Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vicriviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vicriviroc SCHEMBL15375740 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL118885 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4638191 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL29392831 | 0.96 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL19656878 | 0.95 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3321008 | 0.95 | CCR5 (0.90) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14032029 | 0.92 | CCR5 (0.85) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.92 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL15199622 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073358 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020033283-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND VICRIVIROC | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2017201043-A1 | COMBINATION THERAPY FOR TREATING CANCER | CONCERT PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8367674-B2 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20090270336-A1 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1951708-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270336-A1 | Piperazine derivatives | CCR5, CCR2, CXCR3 | CCR5 1/4885CHRM2 2498/4885CHRM1 2938/4885 |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | CCR5 1/4885CHRM2 3987/4885CHRM1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.